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Detection of Major Histocompatibility Complex Class I-Restricted,
HIV-Specific Cytotoxic T Lymphocytes in the Blood of Infected Hemophiliacs
By Richard A. Koup, John L. Sullivan, Peter H. Levine, Doreen Brettler, Anna Mahr,
Gail Mazzara, Sara McKenzie, and Dennis Panicali
Major histocompatibility (MHC)-restricted, human immu-
nodeficiency virus type one (HIV-1 )-specific, cytotoxic T
lymphocytes (CTLs) were detected in the peripheral blood
mononuclear cells (PBMCs) of HIV-i -infected individuals.
Using a system of autologous B and T lymphoblastoid cell
lines infected with recombinant vaccinia vectors (VVs)
expressing HIV-1 gene products. we were able to detect
HIV-i -specific cytolytic responses in the PBMCs of 88% of
HIV-1 -seropositive hemophiliac patients in the absence of
V IRUS-SPECIFIC major histocompatibility (MHC)-
restricted cytotoxic T lymphocyte (CTL) activity is an
effective mechanism through which the immune system can
lyse virally infected cells during acute infection.”2 In addi-
tion, these cells are believed to be important in controlling
viral replication in chronic or persistent virus infections such
as Epstein-Barr virus (EBV) or cytornegalovirus (CM V).3’4
Infection with human retroviruses also appear to stimulate
a virus-specific CTL response. Cytotoxic T lymphocyte lines
specific for HTLV-I have been established from peripheral
blood mononuclear cells (PBMCs) of individuals infected
with this retrovirus.5’6 It has been hypothesized that CTLs
specific for human immunodeficiency virus type one (HIV-
I), the causative agent of AIDS, may play a role in control-
ling replication and spread of this human retrovirus in
asymptomatic seropositive individuals.7 Recently, Walker et
al succeeded in demonstrating the presence of T cells in
PBMCs of HIV-l-seropositive homosexual men that specifi-
cally lyse autologous EBV-transforrned B-lymphoblastoid
cell lines (B-LCLs) that have been infected with recombi-
nant vaccinia virus (VV) vectors expressing HIV-l envelope,
gag, and polymerase gene products.78 These responses
appear to be MHC restricted.
Vectors are excellent tools for measuring virus antigen-
specific CTL responses and have been used extensively in
other viral systems.9 In addition, VV expressing HIV-I
envelope gene products are capable of stimulating HIV-l
envelope-specific CTL responses in vaccinated humans,’#{176}
chimpanzees,” and macaques.’2
In the present study, we used a system of recombinant VV
vectors to detect MHC class I-restricted, HIV-I-specific
CTL responses in the PBMC of HIV-I-seropositive hemo-
philia patients. In addition, we attempted to correlate the
level of these responses with other known determinants of
HIV-I disease progression.
MATERIALS AND METHODS
Patient population. Approximately I 50 patients with hemo-
philia are currently being followed at the New England Area
Comprehensive Hemophilia Center, Worcester Memorial Hospital,
MA, as part of an ongoing prospective study of immunoregulatory
defects in hemophilia.’3 All patients give informed consent before
entering the study and are followed yearly. Approximately 90% of
these individuals are seropositive by Western blot for antibodies to
HIV-l; most seroconverted before 1983.
in vitro stimulation. These cytolytic responses were
directed against both HIV-1 envelope and gag gene prod-
ucts. The responses were resistant to natural killer (NK)
cell depletion and were inhibited by monoclonal antibodies
(MoAbs) to the T cell receptor, CD8 surface antigens. and
MHC class I antigens, suggesting a classical MHC class I
restricted, virus-specific CTL response.
C 1989 by Grune & Stratton. Inc.
Lymphocyte separation. PBMCs were isolated from freshly
drawn heparinized venous blood by centrifugation on Ficoll-
Paque (Pharmacia Fine Chemicals, Piscataway, NJ) density gra-
dients.’3 PBMC preparations contained 70% to 80% lymphocytes,
10% to 20% monocytes, and <20% polymorphonuclear leukocytes as
determined by cell morphology.
Lymphocyte surface marker studies. The relative percentages
of the CD4 and CD8 lymphocyte populations were enumerated
using direct immunofluorescence with phycoerythrin-conjugated
mouse monoclonal antibodies Leu3A and Leu2A (Becton Dickinson,
Mountain View, CA). Samples were analyzed with a FACS 440
(Becton Dickinson). Absolute numbers of lymphocytes per micro-
liter of blood were determined by multiplying the relative percentage
by the absolute number of PBMCs as determined from complete
blood counts.
Virus culture. HIV-l was cultured from PBMC by a modifica-
tion of previously published techniques.’4 PBMCs were cocultivated
with previously phytohemagglutinin (PHA)-stimulated PBMCs
from normal healthy seronegative controls. Cells were maintained in
RPMI 1640, supplemented with 20% heat-inactivated fetal calf
serum (FCS) (GIBCO, Grand Island, NY) and 10% interleukin-2
(IL-2, Electronucleonics, Silver Spring, MD). Cultures were sam-
pled twice weekly for HIV-1 p-24 antigen by electroimmunoassay
(EIA) (Dupont deNemours, Wilmington, DE) and HIV-I genome
by a nonisotopic in situ hybridization technique.’5 Fresh PHA-
stimulated blasts were added weekly, and cultures were maintained
for 3 weeks before being considered negative.
Target cell lines. Autologous B-LCL were created by incuba-
tion of PBMCs with supernatant from the EBV-producing marmo-
set cell line B95.8 (ATCC No. CRL-1612). Autologous T-lympho-
blastoid cell lines (T-LCLs) were created by cocultivation of
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PHA-stimulated PBMCs with an equal number of y-irradiated
( 10,000 rad) MT-2 cells (provided by Dr Miyoshi) according to the
methods of Merl et  All transformed cell lines were maintained
in RPMI 1640 with 10% to 15% FCS. T-LCL cultures were also
supplemented with 10% IL-2 to maintain optimum growth charac-
teristics.
VV vectors. Molecular clones containing sequences encoding
envelope and gaggenes from HIV-l strain BH1O’7 were inserted into
VV strain NYCBH (ATCC No. VR-325) by methods described
previously.’8” Plasmid vectors that direct insertion and expression of
both the HIV-l gene of interest and the Escherichia coli lacZ gene
into the thymidine kinase (tk) locus of VV were constructed. These
plasmids, which contain the HIV-I gene under the control ofthe VV
7.5K promoter,#{176} the E coli lacZ gene under the control of the VV
HindF promotor,2’ and flanking sequences from the VV tk gene
were introduced into BSC-40 cells23 previously infected with VV.
Homologous recombination between plasmid and virus in the tk
region resulted in recombinant viruses selected on the basis of their
TK phenotype22 and identified as blue plaques, due to expression of
fl-galactosidase, in the presence of the chromogenic substrate Bluo-
Gal.2’ Expression ofthe desired HIV-I antigen was confirmed by an
in situ enzyme-linked immunosorbent assay (ELISA) (black plaque
assay) as described below. Recombinant vAbTl4O (I40/env/I60)
contains the entire HIV-l envelope coding sequence as well as 96
base pairs (bp) of 5’ proximal and 107 bp of 3’ proximal untrans-
lanted sequences. Recombinant vAbTl4l (I41/gag/55) contains
the entire HIV-l gag coding sequence beginning at the translation
initiation codon and extending -200 bp beyond the gag translation
termination codon. The predicted molecular structure of the recom-
binant viruses was confirmed by restriction endonuclease analysis
and DNA hybridization ofviral genomic DNA. VV strain NYCBH
was used as the control virus in all CTL studies.
Expression analysis. Expression of the HIV-l antigens by the
recombinant VVs was confirmed in BSC-40 cells by an in situ
ELISA assay performed directly on viral plaques.24 Incubation with
4Dl 2. 1 (monoclonal anti-p55; Epitope, Beaverton, OR) or with
NEA-9303 (monoclonal anti-gp4l; DuPont) was followed by alka-
line phosphatase-labelled goat anti-mouse IgG (AP-GAM; Kirke-
gaard & Perry Labs, KPL) and the precipitating substrate BCIP/
NBT (KPL).
Radioimmunoprecipitations were performed by infecting I x 106
target cells at an MOl of 10, for four hours (BSC-40) or 16 hours
(B-LCL) with 100 jsCi 3H-glucosamine (140/env/160) or 3H-
leucine (141/gag/55). Harvesting and precipitation was performed
as previously described” using mouse monoclonal antibodies
(MoAbs) against HIV-l antigens or pooled HIV-I-positive vaccin-
ia-negative human sera. Cell culture supernatants were assayed for
HIV-I gag antigen by an antigen-capture ELISA assay with a
MoAb system (Dupont). Surface expression of HIV-I envelope
glycoprotein was assessed by the ability of VV-infected cells to form
syncytia with c8 I 66 cells, in a four-hour cocultivation.8
CTL assay. Autologous B-LCLs or T-LCLs were infected or
mock infected with VVs (NYCBH, l40/env/160, l41/gag/55) at a
multiplicity of infection of 10 according to the methods of McMi-
chad et al.9 Sixteen hours later, the cells were washed and incubated
with 100 iCi Na2 (5’Cr04) (New England Nuclear) at 37#{176}Cfor 60
minutes, washed twice with phosphate-buffered saline (PBS), and
resuspended, after viability determination with trypan blue exclu-
sion, to I x l0 cells/mL in RPMI 1640 with 10% FCS. One
hundred-microliter aliquots of target cell suspension were then
dispersed into wells of 96-well round-bottom microtiter plates. To
these wells 100 zL effector cell suspension containing 5.0, 2.5, or
I .25 x I 5 freshly isolated PBMC from hemophilia patients was
then added [effector to target ratio (E:T) = 50, 25, 12.5:1]. Sponta-
neous release wells using RPMI 1640 with 10% FCS in place of
effector cells were included in all assays. Test plates were centri-
fuged at 200 g for five minutes and incubated for six hours at 37#{176}Cin
a humidified, 5% CO2 environment. Plates were then recentrifuged
at 200 g for five minutes, and 100 iL assay supernatant was
collected from each well and counted in a Packard ‘y-counter.
Maximal incorporation was determined by counting the cpm in a
50-tL sample of target cell suspension. All tests were performed in
triplicate.
Percentage of specific cytolysis was calculated by the formula
100 x [(test cpm - spontaneous cpm)/(maximal cpm - sponta-
neous cpm)]. Percentage of HIV-l-specific cytolysis was calculated
by subtracting percentage of specific cytolysis against NYCBH-
infected targets from percentage of specific cytolysis against targets
expressing HIV-I antigens.
Effector cell depletions. Effector PBMCs were depleted of cells
expressing a NK phenotype with a cocktail of the MoAbs Leul lb
and Leu7 (Becton Dickinson) and rabbit complement (Cedarlane
Laboratories, Ontario, Canada) by previously published tech-
niques.2’ Adequacy of the depletions was assessed by inhibition of
killing of the NK-sensitive erythroleukemia cell line K-562 (ATCC-
CCL243) in parallel assays. Percentage ofdecrease in cytolysis after
depletions was calculated by the formula 100 x [(percentage of
specific cytolysis of complement-treated effector cells - percentage
of specific cytolysis of depleted effector cells)/percentage of specific
cytolysis of complement-treated effector cells].
Antibody inhibition studies. MoAbs OKT1 (CD5), OKT3
(CD3), OKT8 (CD8), and W6/32 were prepared from ascites
following intraperitoneal (IP) injection of I to I .5 x l0 hybridoma
cells into previously pristane-treated CAF,, (OKT3, OKT8) or
Balb/C (OKT1, W6/32) mice. MoAb OKIa I was purchased as a
I :3.3 dilution of ascites (Ortho Diagnostics) and dialyzed twice
against PBS to remove azide, resulting in a final dilution of ascites of
1:5. Fifty microliters of a 1:20 dilution of each of these ascites fluids
was added to wells of a 96-well round-bottom microtiter plate
containing I x l0 chromium-label target cells in 50-jzL aliquots.
One hundred microliters of previously N K cell-depleted effector
cells were added to each well for a final E:T ratio of 50: 1 . After
incubation and harvesting as described previously. percentage of
specific cytolysis was calculated as previously described.
Statistical analysis. Data expressed in Figs I through 4 repre-
sent means and n refers to the number of samples tested. Where
present, error bars represent SEM. Significance was determined
when appropriate by analysis of variance (ANOVA), and statistical
significance was defined as P < .05.
RESULTS
vv vector expression analysis. Expression analysis of
VV vector 140/env/160 and 141/gag/55 were published
previously.26 Vector I 40/env/ I 60 produces immunoreactive
bands at gp-4l, 120, and 160 in B-LCLs by radioimmuno-
precipitation, and both B-LCLs and T-LCLs infected with
this vector will form syncytia with c8166 cells when coculti-
vated for four hours. Vector i4i/gag/55 produces a single
immunoreactive band at p-55 in infected B-LCLs, and
HIV-l gag antigen is detectable in B-LCL and T-LCL
supernatants by antigen EIA eight to 24 hours after infec-
tion.
HIV-I-specific cytolysis against B-LCLs. In a standard
chromium release assay, no HIV- i-specific cytolysis of
autologous B-LCL targets could be detected in the PBMCs
of six HIV-l-seronegative controls assayed at E:T ratios of
up to 50:1 (Fig I). In contrast, HIV-I--.specific cytolysis of
autologous B-LCL targets infected with I40/env/I60 or
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and K-562 cells were included as controls. Mean virus-specific
cytolysis before depletion was as follows: gag, 38% (n = 7);
envelope. 24% (n 3). Mean cytolysis before depletion was 43%
(n = 7) against K562 targets. All assays were performed at an E:T
ratio of 50:i.
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141/gag/55 was clearly demonstrable in the PBMCs of 17
HIV-I-seropositive hemophilia patients (Fig 1). These
responses were significantly greater than the responses
against NYCBH-infected targets (P < .01) and were clearly
demonstrable in I 5 of the I 7 (88%) seropositive patients
tested to date. PBMCs from seven of the I 7 seropositive
patients mediated greater cytotoxicity against gag-express-
ing B-LCL targets than against envelope-expressing targets.
Only one patient showed greater cytotoxicity against enve-
lope than against gag-expressing targets; the rest of the
patients showed similar cytotoxicity against both HIV-1
protein-expressing targets. Assays were discarded from anal-
ysis ifspontaneous release was >30%.
HIV-I-specific cytolysis against T-LCLs. Since
B-LCLs from HIV-1-seropositive individuals secrete HIV-
I-specific IgG27 which could mediate cytolysis against tar-
gets expressing HIV-I proteins through antibody-dependent
cell-mediated cytotoxicity (ADCC), PBMCs from six sero-
positive hemophilia patients were assayed for their ability to
mediate cytolysis against autologous T-LCLs infected with
recombinant VV vectors. As shown in Fig 2, T-LCL targets
expressing HIV-l gag or envelope antigens also serve as
appropriate targets for HIV-l-specific cytolysis. Although
the degree of specific cytolysis noted against HIV-I protein-
expressing T-LCL targets was not statistically significantly
greater than the cytolysis noted against vaccinia-expressing
T-LCL targets in this small number of assays and was less
than that noted against B-LCL targets, other work in our
laboratory has shown T-LCLs to be fairly resistant to T cell
lysis and extremely resistant to NK cell lysis (B. Tomkinson,
R. Koup, unpublished observations, November 1987). Since
B-LCL targets appear to be more sensitive to cytolysis than
T-LCL targets, all further reported study results involve
autologous B-LCL targets only.
NK cell resistance ofmeasured cytolysis. To ensure that
the measured cytolysis in these assays was not mediated
Fig 2. Cytotoxicity v B-LCL and T-LCL targets. Cumulative
data from CTL assays on HIV-i -seropositive hemophilia patients,
six of whose PBMCs were reacted against autologous T-LCLs
infected with NYCBH (VAC). i4i /gag/55 (GAG). or i40/env/i60
(ENV). and 1 7 of whose PBMCs were reacted against autologous
B-LCLs similarly infected. Left panel is a duplicate of right panel in
Fig 1 and is reproduced for comparison.
solely by NK cells, either through ADCC or lymphokine-
activated killer (LAK) cell lysis, PBMCs from ten seroposi-
tive patients were depleted of NK cells by antibody-
dependent, complement-mediated lysis. Of these ten
patients, seven had adequate (>20%) HIV-l gag-specific
cytolysis and three had adequate HIV-I envelope-specific
cytolysis to assess the effect of NK cell depletions.
As shown in Fig 3, although NK cell depletion had a
significant effect on lysis of K562 cells, HIV-I-specific
cytolysis against gag- and envelope-expressing B-LCL tar-
gets was only inhibited 23% and I 5%, respectively, indicating
that most of these cytolytic responses were not mediated by
50
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50 25 12.5 50
EffeCtor to Target Ratio
Fig 1 . Cytotoxicity v B-LCL targets. Cumulative data from CTL
assays on six HIV-i -seronegative and i 7 HIV-i -seropositive
hemophilia patients whose PBMCs were reacted against autolo-
gous B-LCLs infected with NYCBH (VAC). i4i /gag/55 (GAG). or
i40/env/i60 (ENV). in a six-hour chromium release assay.
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NK cells. In addition, the low level ofcytolysis noted against
NYCBH-infected B-LCL targets was inhibited almost com-
pletely by NK cell depletion (75%) and probably represents a
slight NK cell sensitivity of these virally infected cell (data
not shown).
MoAb inhibition studies. To determine the cellular on-
gin and MHC restriction of the cytolytic responses remain-
ing after NK cell depletions, MoAbs were added to the CTL
assays to inhibit specific cytolysis. PBMCs from four
patients had >1 5% gag-specific cytolysis, and PBMCs from
one patient had  I 5% envelope-specific cytolysis after NK
A
B
C
D
0 10 20 30 40 50
PERCENT HIV-1 GAG-SPECIFIC CYTOLYSIS
E
i’D 20 30 40 50
PERCENT HIV-1 ENV-SPECIF1C CYTOLYSIS
Fig 4. Effect of MoAbs on specific cytolysis. PBMCs from
HIV-1 -seropositive hemophiliac patients with 1 5% gag- or enve-
lope-specific cytolysis after depletion of NK cells, were reacted
against autologous B-LCLs infected with VV vectors, with addition
of an excess of mouse MoAbs OKT1 . 0KT3. OKT8, W6/32. or
OKIal . All assays were run at an E:T ratio of 50:1 for six hours;
n.d.. not done because of inadequate number of effector cells.
cell depletion; the results of MoAb inhibitions on these five
individuals are shown in Fig 4. MoAbs used were OKT3
which is directed against the CD3 protein of the T-cell
receptor and inhibits antigen-specific T-cell-dependent kill-
ing,28 OKT8 which is directed against the CD8 surface
antigen, W6/32 which is directed against common determi-
nants on MHC class I molecules and inhibits cytolysis by
class I-restricted CTL clones,28’2’ and OKIa1 which is
directed against common determinants on MHC class II
molecules and inhibits cytolysis by class Il-restricted CTL
clones.29 OKT1 was used as a control, being directed against
a pan T-cell marker, CD5, and does not affect T-cell-
mediated cytolysis.28’#{176}
As is expected of cytolysis mediated by virus-specific,
MHC class I-restricted CTLs, the HIV-1-specific cytolysis
against autologous targets expressing gag proteins was inhib-
ited by MoAbs OKT3, OKT8, and W6/32, but not OKTI or
OKIal , and the specific cytolysis against envelope-express-
ing targets appear to follow a similar pattern (Fig 4). This
inhibition of cytolysis does not represent a nonspecific phe-
nomenon as cytolysis by CD4-positive, class Il-restricted,
dengue virus-specific CTL clones is inhibited by these same
OKT3 and OKIa1 preparations, but not by the W6/32 or
OKT8 preparations (I. Kurane, personal communication,
April 1988).
Correlations to clinical predictors of disease pro-
gression. All 1 7 of the seropositive hemophiliac patients
described in this study were asymptomatic, falling into CDC
group II or III classifications.3’ When the level of gag- or
envelope-specific CTL responses in these individuals was
compared with absolute CD4 or CD8 lymphocyte counts or
ratios of helper to suppressor cells, no positive correlations
could be determined. However, when we compared the level
of gag- or envelope-specific CTL with the ability to detect
HIV-l in PBMC cultures, PBMCs that did not yield HIV-l
in culture appeared to have more vigorous CTL responses
than PBMCs that did yield virus on cocultivation (Table I).
This difference did not reach statistical significance (P < . I,
gag; P < .3, env) in this small patient population, however.
DISCUSSION
The present study was designed to confirm and extend the
observations of Walker et a18 that HIV-I-specific CTL re-
sponses directed against envelope, and to a lesser degree, gag
gene products were detectable in PBMCs of HIV-I-sero-
positive subjects in the absence of in vitro stimulation. Our
results support the observation of Walker et al with some
significant differences. Our studies have detected much more
vigorous CTL responses against gag-expressing targets in
this hemophiliac population than in the homosexual popula-
tion studied by Walker et al.8 This could relate to differences
in the immune response to HIV-l in these two distinct popu-
lations, differences in the stage of disease at which the re-
sponses were measured, or subtle differences in the level of
gag antigen expression by the different VV vectors used in
these two studies. We therefore believe this to be the first
description and characterization of high-level gag-specific
CTL activity in PBMCs of seropositive individuals.
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Table 1 . HIV-1 -Specific CTL Responses in Culture-Negative and Culture-Positive Hemophilia Patients
Patient
Percentage of Specific Cytolysis v Autologous B-LcLs Infected With
VAC GAG ENV
HIV-1 culture-negative(n - 8) 8.9 ± 3.2 51.1 ± 7.1 36.9 ± 7.2
HIV-1 culture-positive(n - 9) 4.9 ± 1.3 33.4 ± 6.3 27.7 ± 3.7
Comparison of level of virus-specific CR Iysis with ability to isolate HIV- 1 from PBMCs. Cultures were performed for 3 weeks and sampled twice
weekly for HIV-1 p-24 antigen by EIA and HIV-l genome by in situ hybridization. Virus-specific CR assays were run at an E:T ratio of 50: 1 ; data are
mean ± SEM.
The level of virus-specific CTL measured in these studies
is without precedent in other persistent viral infections,
including the related human retrovirus HTLV-I.5’6 These
high and sustained responses may be a result of constant in
vivo stimulation of CTL by ongoing viral replication, or the
measured responses may not represent true MHC-restricted
CTL responses but instead represent the activity of either
NK cells or killer cell-mediated ADCC.26’32 As would be
expected in bulk PBMC assays, more than one mechanism
may be contributing to the measured cytolysis. The responses
measured by Walker et al appear to be T cell mediated,7’8
whereas similar responses measured against targets absorbed
with gp-120 by Weinhold et al appear to be NK cell
mediated.32 Our studies indicate that a small but distinct
proportion (15% to 25%) of the measured HIV-I-specific
cytolysis can be eliminated by depleting effectors of cells
bearing the CDI6 phenotype. Cells of this phenotype
mediate cell killing through direct mechanisms or through
ADCC.26’32 We believe that the former mechanism is most
likely responsible for the low level of NK-cell sensitivity
observed in this system since we previously showed that
B-LCLs infected with 141/gag/55 do not present viral
antigens on their surface capable of mediating ADCC.26
The remainder of the cytolytic response against targets
expressing HIV-I proteins does appear to follow the charac-
teristics of a classical virus-specific MHC class I-restricted
CTL response, being inhibited by MoAbs to CD3, CD8, and
MHC class-I, but not CD5 or MI-IC class II. In our MoAb
inhibiting system, we found it important first to deplete
effectors of NK cells to avoid augmenting cytolysis through
the action of cells bearing FC-receptors.33 Although a restric-
tion was noted by Walker et a18 against targets expressing
HIV-l envelope products, the class I or class II restriction
pattern was not readily apparent from the data and suggests
that both CD4 and CD8 clones may have been responsible
for the T-cell-mediated killing measured in his assays.
HIV-l gp-1 20-specific CTL clones derived from lympho-
cytes in the CSF of HIV-I-infected individuals have both
MHC class I and MHC class II restriction patterns.34 Most
of the l-lIV-l gag-specific CTL responses measured in our
population, however, appear to be mediated by CD8, MHC
class I-restricted CTL, as evidenced by strong inhibition by
antibodies to CD8 and class I antigens, whereas the enve-
lope-specific responses may be mediated by both class I- and
class lI-restricted CTL since incomplete inhibition of killing
was noted with class I-specific antibodies.
Several prognostic indicators of disease progression from
the asymptomatic state to AIDS-related complex (ARC) or
AIDS have been described, including loss of antibody to
p-24,35 appearance of p-24 antigen in serum,35 loss of CD4
lymphocytes,36 and decrease in helper to suppressor ratio.
We previously described the ability to isolate HIV-l from the
PBMCs of asymptomatic l-IIV-l-seropositive hemophiliac
patients as being strongly predictive of disease progression.’4
The inability to isolate HIV-l from the PBMCs of asymp-
tomatic seropositive hemophilia patients may correlate with
more vigorous HIV-1-specific CTL responses. Although this
association does not yet reach statistical significance, we
hope to confirm or deny this initial observation as we
continue to follow this patient population. The presence of
circulating HIV-l-specific CTL in these virus culture-
negative but seropositive hemophiliac patients indicates that
they have been infected with live virus and not just immu-
nized with inactive virus. In addition, the high level of CTL
response in these patients from whom HIV-l cannot be
isolated may be indicative of low-level virus replication that
is controlled by an effective immune response.
In summary, we confirmed the findings of previous investi-
gators and detected l-IIV-l-specific CTL responses in
PBMCs of infected hemophilia patients in the absence of in
vitro stimulation. Most of these cytolytic responses appear to
be NK cell resistant, T cell mediated, and MHC class I
restricted. These responses are directed against both HIV-I
gag and envelope antigens, and the generation of these
responses in vivo may be one way in which the human
immune system can adequately deal with this devastating
infection.
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